Study developed a protamine-loaded nanocomposite, improving antibacterial efficacy against MDR bacteria, suggesting enhanced therapeutic potential.
The emergence of multidrug-resistant (MDR) bacterial infections has become a critical global health concern, driving the urgent need for innovative therapeutic strategies beyond conventional antibiotics. In this study, we developed a novel nanotherapeutic platform comprising protamine-loaded poly(N-vinyl-2-pyrrolidone)-stabilized silver nanoparticles (PVP-AgNPs) designed to enhance antimicrobial efficacy while improving biocompatibility. AgNPs were synthesized via chemical reduction using silver nitrate and sodium borohydride, with PVP serving as a stabilizing and capping agent. Protamine sulfate, a cationic antimicrobial peptide, was subsequently incorporated to exploit its strong affinity for bacterial membranes and synergistic bactericidal effects. The resulting nanoparticles exhibited spherical morphology with an average diameter of 70.96 ± 0.27 nm, a PDI of 0.25 ± 0.002, a zeta potential of +10.4 ± 0.15 mV, and a protamine loading efficiency of 66.2% ± 3.2%, indicating excellent colloidal stability and drug incorporation. In vitro antimicrobial testing demonstrated a two- to four-fold reduction in minimum inhibitory concentration values compared to blank PVP–AgNPs and free protamine, with disk diffusion assays confirming significantly enhanced activity against both Gram-positive ( Staphylococcus aureus ) and Gram-negative ( Escherichia coli, Pseudomonas aeruginosa ) bacteria. Furthermore, in vivo evaluation using a murine wound infection model showed effective bacterial clearance, accelerated wound closure, and improved tissue regeneration. These findings demonstrate that protamine-loaded PVP-AgNPs offer multimodal antibacterial activity, enhanced cytocompatibility, and the potential to overcome resistance mechanisms. Collectively, this work introduces a promising nanotherapeutic strategy for managing MDR infections and promoting wound healing, with significant implications for future biomedical applications.
No takes yet. Share an insight, caveat, or question.
Jaafreh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: